{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-139959","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.243685+00:00","generated_at":"2026-05-19T10:46:34.820287+00:00","sec_items":["1.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verrica amends credit agreement, waives going concern covenant through Dec 2025","bullets":["Sixth amendment waives Section 7.1(b) and 7.1(c) going concern qualifications for Q2'25, Q3'25, and FY2025 financial statements.","Company paid amendment fee of $110,465.12 to lenders (OrbiMed Royalty & Credit Opportunities IV, LP).","Original credit agreement dated July 26, 2023; all other terms unchanged.","Waiver addresses potential default risk from going concern audit language in upcoming filings."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-139959","json":"https://secwatch.observer/filing/0001193125-25-139959.json","markdown":"https://secwatch.observer/filing/0001193125-25-139959.md","text":"https://secwatch.observer/filing/0001193125-25-139959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525139959/0001193125-25-139959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525139959/d949783d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T10:46:34.820287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}